Re: Re: Re: [MSWatchers] FDA approves Ampyra for MS

[Guest guest]

This is 4-AP. The difference is that 4-AP is quick release and Ampyra (or Fampridine) is a slow release. I have been taking 4-AP and have suffered no side effects. I take three 5mg capsules of 4-AP two - three times a day at 4 hour intervals. It doesn't help my mobility but does lessen my stiffness a little.CarolynFrom: LarryGC <larrygc@...>To:

MSWatchers Cc: LDN group <low dose naltrexone >; Spotlight_LDN <Spotlight_ldn >Sent: Sun, January 24, 2010 7:28:46 PMSubject: [low dose naltrexone] Re: Re: [MSWatchers] FDA approves Ampyra for MS



Is this 4-AP? side effects don't look too good though.

http://www.drugs. com/ampyra. html

Important Safety Information for Ampyra

Ampyra Contraindications

Ampyra can cause seizures; the risk of seizures increases with increasing Ampyra doses. Ampyra is contraindicated in patients with a prior history of seizure. Discontinue Ampyra use if seizure occurs.

Ampyra is contraindicated in patients with moderate to severe renal impairment (CrClless-than or equal to 50 mL/min); the risk of seizures in patients with mild renal impairment (CrCl 51-80 mL/min) is unknown, but Ampyra plasma levels in these patients may approach those seen at a dose of 15 mg twice daily, a dose that may be associated with an increased risk of seizures; estimated CrCl should be known before initiating treatment with Ampyra.

Ampyra should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same.

Ampyra side effects

Urinary tract infections were reported more frequently as adverse reactions in patients receiving Ampyra 10 mg twice daily compared to placebo.

The most common adverse events (incidence greater-than or equal to 2% and at a rate greater than the placebo rate) for Ampyra in MS patients were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain.

About Ampyra (dalfampridine)

Ampyra is a potassium channel blocker approved as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. Ampyra, which was previously referred to as Fampridine-SR, is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP), which was previously called fampridine. In laboratory studies, dalfampridine has been found to improve impulse conduction in nerve fibers in which the insulating layer, called myelin, has been damaged.

[MSWatchers] FDA approves Ampyra for MS"msWatchers" <mswatchers@gro ups.com>Cc: "LDN group" <low dose naltrexone>, "Spotlight_LDN" <Spotlight_ldn>Date: Sunday, January 24, 2010, 4:25 PM

http://www.cnn. com/2010/ HEALTH/01/ 22/fda.approval. ms.drug/

The FDA says the drug, Ampyra (generic name dalfampridine, formerly known as fampridine), is the first MS therapy that is taken orally and the first of its kind to receive FDA approval. It is designed help people with any type of MS improve their walking speed.

Haven't heard from anyone online using this med, I wonder how will it would work with LDN, I'd love to be able to walk and maybe run again.